Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 41.21
-3.75 (-8.34%)
At close: Jun 2, 2026
Shanghai OPM Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 452.91 | 354.44 | 296.78 | 242.69 | 294.27 | 212.68 |
Other Revenue | 0.48 | 0.48 | 0.47 | 0.43 | 0.1 | - |
| 453.39 | 354.91 | 297.24 | 243.12 | 294.37 | 212.68 | |
Revenue Growth (YoY) | 50.52% | 19.40% | 22.26% | -17.41% | 38.41% | 70.19% |
Cost of Revenue | 251.19 | 182.2 | 142.34 | 101.53 | 107.25 | 86 |
Gross Profit | 202.2 | 172.72 | 154.9 | 141.59 | 187.12 | 126.69 |
Selling, General & Admin | 126.05 | 96.12 | 105.94 | 74.47 | 60 | 50.96 |
Research & Development | 51.73 | 47.41 | 33.37 | 41.91 | 32.19 | 19.03 |
Other Operating Expenses | 2.74 | 4.08 | 2.21 | -0.23 | 1.17 | 0.78 |
Operating Expenses | 183.19 | 150.27 | 148.44 | 122.57 | 98.11 | 71.09 |
Operating Income | 19.01 | 22.45 | 6.46 | 19.02 | 89 | 55.6 |
Interest Expense | -2.69 | -2.69 | -3.12 | -3.23 | -4.98 | -4.79 |
Interest & Investment Income | 39.54 | 43.65 | 31.14 | 36.3 | 17.98 | 9.07 |
Currency Exchange Gain (Loss) | -5.09 | -5.09 | 2.4 | 0.87 | 2.24 | -0.24 |
Other Non Operating Income (Expenses) | -6.53 | -0.06 | -0.05 | -0.09 | -0.14 | -0.07 |
EBT Excluding Unusual Items | 44.23 | 58.25 | 36.84 | 52.89 | 104.09 | 59.57 |
Gain (Loss) on Sale of Investments | 27.43 | -4.89 | 4.63 | 1.53 | 1.67 | - |
Gain (Loss) on Sale of Assets | -0.06 | -0.03 | 0.09 | -0.02 | 0.29 | -0.02 |
Asset Writedown | -10.01 | -9.55 | -7.51 | - | - | - |
Other Unusual Items | 5.59 | 5.59 | 2.38 | 7.26 | 13.38 | 8.61 |
Pretax Income | 67.17 | 49.37 | 36.43 | 61.67 | 119.43 | 68.15 |
Income Tax Expense | 3 | 8.36 | 16.19 | 8.41 | 14.06 | 7.76 |
Earnings From Continuing Operations | 64.17 | 41.02 | 20.24 | 53.26 | 105.37 | 60.39 |
Minority Interest in Earnings | 2.09 | 0.68 | 0.82 | 0.78 | - | - |
Net Income | 66.26 | 41.7 | 21.05 | 54.04 | 105.37 | 60.39 |
Net Income to Common | 66.26 | 41.7 | 21.05 | 54.04 | 105.37 | 60.39 |
Net Income Growth | 310.49% | 98.07% | -61.04% | -48.72% | 74.47% | 416.87% |
Shares Outstanding (Basic) | 117 | 113 | 111 | 115 | 101 | 86 |
Shares Outstanding (Diluted) | 225 | 113 | 117 | 115 | 101 | 86 |
Shares Change (YoY) | 93.00% | -3.64% | 1.72% | 13.48% | 17.43% | 0.20% |
EPS (Basic) | 0.57 | 0.37 | 0.19 | 0.47 | 1.04 | 0.70 |
EPS (Diluted) | 0.30 | 0.37 | 0.18 | 0.47 | 1.04 | 0.70 |
EPS Growth | 112.69% | 105.56% | -61.70% | -54.81% | 48.57% | 415.84% |
Free Cash Flow | -1.96 | 47.32 | -51.61 | -19.59 | -35.34 | 8.64 |
Free Cash Flow Per Share | -0.01 | 0.42 | -0.44 | -0.17 | -0.35 | 0.10 |
Dividend Per Share | 0.430 | 0.430 | 0.420 | 0.440 | 0.429 | - |
Dividend Growth | 2.30% | 2.30% | -4.47% | 2.66% | - | - |
Gross Margin | 44.60% | 48.67% | 52.11% | 58.24% | 63.57% | 59.56% |
Operating Margin | 4.19% | 6.33% | 2.17% | 7.82% | 30.23% | 26.14% |
Profit Margin | 14.61% | 11.75% | 7.08% | 22.23% | 35.80% | 28.40% |
Free Cash Flow Margin | -0.43% | 13.33% | -17.36% | -8.06% | -12.01% | 4.06% |
EBITDA | 60.36 | 62.75 | 42.56 | 47.04 | 113.28 | 74.34 |
EBITDA Margin | 13.31% | 17.68% | 14.32% | 19.35% | 38.48% | 34.96% |
D&A For EBITDA | 41.35 | 40.3 | 36.1 | 28.02 | 24.28 | 18.74 |
EBIT | 19.01 | 22.45 | 6.46 | 19.02 | 89 | 55.6 |
EBIT Margin | 4.19% | 6.33% | 2.17% | 7.82% | 30.23% | 26.14% |
Effective Tax Rate | 4.47% | 16.92% | 44.45% | 13.63% | 11.78% | 11.39% |
Revenue as Reported | 354.91 | 354.91 | 297.24 | 243.12 | 294.37 | 212.68 |
Advertising Expenses | - | 3.11 | 2.08 | 2.29 | 1.34 | 0.73 |